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INTRODUCTION
The 2nd International Conference on High Dose Chemotherapy: Innovation and Evolution was held 
April 9-12, 2002, in Banff, Alberta, Canada. It was the follow-up conference to the successful EBMT Interna-
tional Conference on High Dose Chemotherapy in Breast and Ovarian Cancer which was held in Florence,
Italy, in September 2000. In the last two years, the transplantation for solid tumors has been experiencing a
major shift in thinking. Only randomized prospective Phase III studies representing level I evidence will be
taken into consideration in the future. Data derived from such studies will change clinical practices. It is expected
that survival beneﬁt must be identiﬁed in a magnitude that is exceeding the usual. Statistical signiﬁcance will
not be sufﬁcient and major clinical impact must be identiﬁed. Due to such a shift in thinking about high dose
chemotherapy for solid tumors, our subtitle “Innovation and Evolution” was chosen to identify the new devel-
opments of the transplantation concept. At our conference, three topics were covered by the distinct interna-
tional faculty. The ﬁrst session dealt with high dose chemotherapy and reports on phase III trials in metastatic
breast cancer, high-risk early breast cancer, and ovarian cancer from North America, Europe, Australia, and
Japan. The second session dealt with immunotherapy using the cellular product (allogeneic and autologous) or
monoclonal antibodies. Finally, the third session focused on targeted therapeutics which have experienced a
tremendous boom over the last three years. The identiﬁcation and sequencing of the human genome with its
logical consequence proteonomics has allowed researchers to identify molecular pathways that are instrumental
in tumorgenesis. Whether or not we can use these targets for therapy and how to deal with the novel molecules
in clinical studies was the topic concluding the scientiﬁc sessions.
On the following pages, please ﬁnd the abstracts of papers that were presented along with the abstracts that
were accepted for the poster session. I trust that the goal to identify the status of high dose chemotherapy as
well as its innovation and evolution was met. We will reconvene for the 3rd International Conference on High
Dose Chemotherapy in Ankara, Turkey, in September 2004.
Stefan Glück, MD, PhD
President and Scientiﬁc Co-Chair
Professor, Dept. Oncology, Medicine and Pharmacology & Therapeutics
Faculty of Medicine, University of Calgary
Senior Leader, Clinical Research Program
Medical Oncologist, Tom Baker Cancer Centre
Calgary, Alberta, Canada
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A new EBMT 9 study comparing high-dose chemotherapy
(HDC) and autologous stem cell transplantation (ASCT)
with conventional chemotherapy in patients with plat-
inum sensitive epithelial ovarian cancer
T. Demirer. From EBMT Solid Tumor Working Party Registry, Ankara,
Turkey
Primary objective of this study is to compare the 2-year progres-
sion-free survival between HDC and standard dose chemotherapy
in patients with relapsed platinum sensitive ovarian cancer. Sec-
ondary objectives are 3-year survival, quality of life and compari-
son of toxicity. This is a prospective, multicenter, open and ran-
domised comparison in which the sample size will be 220 patients,
110 in each treatment group. Patients with relapsed platinum sen-
sitive epithelial ovarian cancer (duration of initial CR > 6 months)
who had an optimal surgical and/or chemodebulking after relapse
will be accrued into this study. Patients, following an initial 3 cycles
of carboplatin + paclitaxel, will be randomized to receive either
further conventional chemotherapy or HDC. High-dose arm, ini-
tially, will receive cyclophosphamide + paclitaxel + G-CSF for fur-
ther cytoreduction and mobilization of peripheral blood stem cells
prior to HDC with TMCb regimen (thiotepa, melphalan and car-
boplatin) or CMC regimen (cyclophosphamide, mitoxantrone,
carboplatin) or carboplatin + melphalan and ASCT. Following an
initial 3 cycles of carboplatin + paclitaxel, conventional arm will
receive 3 more cycles of chemotherapy containing carboplatin
alone at 3-week intervals. This study was activated in January
2002 and will be ﬁnished in 3 years.
Front-line high-dose chemotherapy trials in ovarian cancer
M. Prince. Blood and Marrow Transplant Service, Division of Haematology and
Medical Oncology, Peter MacCallum Cancer Institute (PMCI), Melbourne, Aus-
tralia
High-dose therapy (HDT) with peripheral blood progenitor cell
(PBPC) support achieves high-response rates (RR) and durable
remissions in selected patients with relapsed ovarian cancer
(OvCa). Consequently, investigators have more recently been
exploring the feasibility of applying HDT as front-line treatment
for patients (pts) with OvCa. However, there is comparatively
little data in this setting. Indeed, only 8% of transplants for
OvCa reported to the ABMTR were for front-line therapy.
Nonetheless, this registry report demonstrated that this poor
prognosis group had promising outcomes with 2 yr PFS and OS
of 35% and 60%, respectively (Ann Int Med v133; pp504. 2000).
In general, 2 strategies of front-line HDT have been adopted: a
“consolidation” approach following conventional-dose therapy
(CDT) and a “repetitive/sequential” approach.
Consolidation approach: Stiff et al (JCO v15; pp1309. 1997)
previously identified that pts with low-bulk, platinum-sensitive
disease have the best outcome following HDT. This is supported
by the registry data of the EBMT (Ann Oncol v12; pp583. 2001)
and ABMT (Ann Int Med v133; p504. 2000). Thus with the “con-
solidation” approach, pts with chemotherapy-sensitive disease to
CDT, undergo a subsequent single cycle of HDT. The utilization
of initial CDT achieves 2 goals; it identiﬁes pts most likely to ben-
eﬁt from HDT and achieves tumour-bulk reduction. A number of
Phase II studies have examined this approach (Legros, Viens,
Extra, Menichella, Holmberg) and report PFS of approx 45-50%
at 2 yrs. HDT regimens have been variable and most commonly
include carboplatin (Cb), melphalan (M) and cyclophosphamide
(CTX). Most recently, Salerno et al (BMT v27; p1017. 2001)
reported the results of 55 pts with minimal disease following ini-
tial CDT, who subsequently received HDT with Cb (1200mg/m2),
etoposide (900mg/m2) and M (100mg/m2). At a median FU of
55mo, the median TTP was 35 mo with predicted 5 yr TTP of
35%. The GINECO group (Cure et al. ASCO 2001 #815)
recently presented the results of the only completed randomized
trial; 110 patients who had received 4-6 cycles of platinum-based
chemotherapy with <2cm residual disease following 2nd look
surgery, were randomized to receive a single cycle of Cb
(1600mg/m2) + CTX (6g/m2) with PBPC support [HDT-arm], or
3 further cycles of Cb (300mg/m2) and CTX (600mg/m2) [CDT-
arm]. At a median follow-up of 44 months, pts in the HDT-arm
had a superior DFS (22 v 10mo; p=0.03).
Repetitive/sequential approach: With this approach, all pts
proceed rapidly to early PBPC collection and repeated cycles of
HDT. Of note, this strategy does not select out patients with dis-
ease inherently resistant to CDT; a group destined to do poorly.
When analysing the outcome data, it is important to consider this
latter point. The repetitive HDT approach is attractive because it
not only allows one to escalate drugs beyond the conventional-
dose range, but also enhance dose-intensity by administering the
drugs in rapid succession. In general, investigators have either
administered single agents in a sequential fashion, or combined
classic conventional-dose combinations in higher doses. The strat-
egy of sequential cycles of HDT was ﬁrst explored by investiga-
tors at MSKCC (Fennelly, Crown et al), utlizing regimens with
sequential Cb, thiotepa and paclitaxel (P). A similar strategy has
been explored by Wandt et al (BMT v23; pp763. 1999). These
studies included pts with relapsed and poor-prognosis disease.
More recently, we (PMCI) and investigators at Fox Chase Cancer
Center (FCCC) have investigated the combination of 3 of the
most active agents in OvCa – paclitaxel, Cb and topotecan.
Indeed, combining these 3 drugs without PBPC is not possible
(because of dose-limiting thrombocytopenia), thus in the absence
of PBPC, combination therapy can only be applied by using regi-
mens with substantial dose reductions of the individual agents.
The PMCI group (n=19) demonstrated a MTD of Cb (AUC=12),
P (250 mg/m2) and topotecan (3.5 mg/m2/day for ﬁve days = total
of 17.5mg/m2). The clinical RR was 95% with a clinical CR rate
of 73% and pathological CR of 61%. At an updated median fol-
low-up of 4 yrs, the median PFS is 30 mo and 5yr predicted PFS
and OS of 24% and 67%, respectively (Gynae Oncol v81: pp216.
2001). Despite these promising results, the true efﬁcacy can only
be demonstrated in a randomized trial. As the next step, a Phase II
study using the Fox Chase dosing regimen (JCO v19: pp1021.
2001) is currently underway through the GOG (GOG-9903).
The randomized EBMT OVCAT (EU-99040) study remains
open to accrual (target =300) with patients in the HDT arm
receiving 2 cycles of CTX (3g/m2) + paclitaxel (200mg/m2) fol-
lowed by 2 cycles of Cb (AUC=20) + P (200mg/m2) and the ﬁnal
cycle adding M (140mg/m2).
In summary, the poor outcome of patients with advanced OvCa
following CDT warrants that novel approaches be explored.
HDT is one such approach. Early results using either consolida-
tive or repetitive HDT demonstrate the feasibility of these
approaches with promising results. However, randomized trials
need to completed and analyzed after reasonable follow-up before
deﬁnitive conclusions can be drawn.
High dose chemotherapy: Pegase trials
H. Roché. Institut Claudius Regaud, Toulouse, France
Since 1994, the Pegase program has opened 7 trials to explore
the impact of high dose chemotherapy treatments in breast can-
cer. This national program is supported by the French Federa-
tion of Anti cancer centers, the French Society for Bone Marrow
Transplantation, public and private funds. In 1993, a concensus
conference on intensive chemotherapy gave the rules to accredite
the value of this new approach (Lyon). So, pilot studies for inﬂam-
matory disease and randomized phase III in adjuvant and metasta-
tic setting were launched.
For inflammatory breast cancer, two phase II (P 02 and 05)
using sequential high dose treatments with Adriamycin and
Cyclophosphamide before surgery demonstrated high level of his-
tologic complete response, but major toxicities when taxotere was
added to these two drugs. An on-going phase III trial is now
assessing the value of Taxotere and 5 FU after surgery (P 07).
For metastatic disease, intensiﬁcations with Cyclophosphamide-
thiotepa (P 03) or Cyclophosphamide-Mitoxantrone-alkeran
(CMA)(P 04) was compared to observation for responding
patients to FEC100 (P 03) or miscellanous regimens (P 04). The
ﬁrst results of P 03 trial will be soon presented at the next ASCO
meeting. P 04 demonstrated better outcome in the intensified
arm, but an insufﬁcient accrual does not permit clear conclusions.
Finally, the P 01 trial concerned non metastatic, high-risk breast
cancer patients. After 4 cycles of FEC 100, one cycle of CMA was
randomized versus nothing. 314 patients entered this study.
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Toxicity was easily manageable. The first planned analysis with
33 months of follow-up led to observe a signiﬁcant better disease-
free survival in the high-dose arm without yet survival beneﬁt. An
update of the trial and companion studies on quality of life and
costs will be presented at the conference. A new ongoing trial is
comparing standard 6 FEC 100 to 4 cycles of intensiﬁed epiru-
bicin-cyclophosphamide combination for the same non metastatic
population (P 06).
High-dose chemotherapy as consolidation therapy for
patients with platinum-sensitive advanced epithelial ovar-
ian cancer: The French experience with preliminary
results of the GINECO/FNCLCC/SFGM-TC phase III random-
ized trial
H. Cure,1 D. Paraiso,2 J.P. Lotz,3 C. Battista,4 J.M. Extra,5 P. Viens,6
J.P. Guastalla,7 J.O. Bay,1 J. Dauplat,1 C. Lhomme,8 E. Pujade Lau-
raine.2 1Centre Jean Perrin, Clermont-Ferrand; 2Hôtel-Dieu, Paris; 3Hôpital
Tenon, Paris; 4Napoli, Italie; 5Institut Curie, Paris; 6Institut Paoli-Calmettes,
Marseille; 7Centre Léon Berard, Lyon; 8Institut Gustave Roussy, Paris
Patients with advanced ovarian cancer (AOC) have a poor short-
term prognosis with a survival rate under 15% at 5 years. There-
fore, from 1983 to 1995, several French medical teams separately
initiated phase II studies of high-dose chemotherapy (HDC) with
the support of an autologous stem cell transplantation (ASCT).
Results were very encouraging: only 2% of toxic death and one
fourth of long-term survivors with a median disease free survival
(DFS) of 18 months. Moreover, these studies have suggested that
HDC is most effective in chemosensitive AOC patients with low
tumor burden [1-4].
That’s why we investigated from July 1995 to October 2000 a
prospective multicentric phase III trial (the GINECO/FNCLCC/
SFGM-TC study) [5]. We compared DFS and toxicity of women
with AOC randomized after second-look operation (SLO) to
receive either HDC Carboplatin-Cyclophosphamide and PBSC
support (Cb 400 mg/m2/d and Cy 1500 mg/m2/d x 4 days) or 3 cycles
of conventional-dose maintenance (CDM) (q4w, Cb 300 mg/m2,
Cy 500 mg/m2). Eligibility criteria were: age <60 yrs, FIGO stage
III-IV, disease responsive to 4-6 cycles of a platinum-based ﬁrst-
line chemotherapy, tumor size <2 cm at the end of the SLO or a
pathological complete response (pCR) but high-risk factors. One
hundred ten patients were enrolled. Patient’s characteristics were
well balanced. Half of the patients received paclitaxel in ﬁrst-line.
Ten had Stage IV and 100 had stage III with at SLO: pCR (39%),
microscopic (20%) and macroscopic (41%) disease. Ten patients
(19%) did not receive the HDC because of poor PBSC mobiliza-
tion (n= 6), patient refusal (n=3) or early relapse (n=1). Median
time to neutrophil and platelets recovery was 11 days. One patient
died from toxic myocarditis. Currently, 102 patients are eligible
for intent-to-treat analysis (52 HDC, 50 CDM). The median fol-
low-up is 36 months. Sixty-seven patients have relapsed. Median
DFS from inclusion was 11 months in the CDM arm and 22
months in the HDC arm (p =.03). In multivariate analysis, inde-
pendent predictive factors for low relapse rate were presence of
paclitaxel in ﬁrst-line regimen (p=.005), low tumor burden at SLS
(p=.01) and consolidation treatment with HDC (p=.02).
A randomized trial of high-dose chemotherapy (HDCT)
with autologous peripheral blood stem cell support (ASCT)
compared to standard chemo therapy (CT) in women with
metastatic breast cancer: A National Cancer Institute of
Canada (NCIC) clinical trials group study
M. Crump and S. Glück. For the National Cancer Institute of Canada Clinical
Trials Group, Kingston, Ontario, Canada
In April 1997 we initiated a multi-centre, randomized trial to
compare overall survival and quality of life of women with
chemosensitive metastatic breast cancer treated with 6 cycles of
standard induction chemotherapy and then either one consolida-
tion treatment with cyclophosphamide 1500 mg/m2, mitoxantrone
70mg/m2, carboplatin 450 mg/m2 + ASCT, or continued stan-
dard-dose therapy. Between 7/1997 and 12/2000, 386 patients
were registered, and 224 randomized: 112 to HDCT + ASCT and
112 to standard CT. Median age was 46 and 47.8 yrs; 32% hor-
mone receptor neg., 31% progressed on/after prior Tam, 30%
HR+ and no prior Tam; 67% received anthracycline based induc-
tion therapy and 33% taxane based. Complete remission rates
prior to randomization were 11 and 12 % respectively.
Results: 55 deaths in each arm were observed; 7 (6%) patients
on the HDCT arm died of toxicity. The intent to treat analysis
resulted in a median overall survival of 1.98 years for HDCT and
2.31 years for standard treatment (95% CI 1.7 – 3.18 and 1.55 –
2.55). The hazard ratio for survival is 1.01, P = 0.96. The pro-
gression free survival analysis revealed a hazard ratio of 1.49
(95% CI 1.080-2.046) in favor of HDCT. For this analysis there
were 69 (62%) events vs. 84 (76%) events, P = 0.01. 21% of all
patients assigned to HDCT did not undergo ASCT due to dis-
ease progression or withdrawal of consent. Subset analysis did not
identify any group of women who beneﬁted from HDCT com-
pared to standard therapy, although the power to detect such a
difference was small. 
Conclusion: HDCT+ASCT as given in this study does not
improve survival for patients with metastatic breast cancer when
used as consolidation treatment after 6 cycles of induction
chemotherapy, compared to standard-dose therapy.
Randomized phase III study of high-dose chemotherapy
with autologous stem cell support as consolidation in
high-risk postoperative breast cancer: Japan Clinical
Oncology Group
Y. Tokuda, T. Tajima, M. Narabayashi, K. Takeyama, T. Watanabe,
T. Fukutomi, T. Chou, M. Sano, T. Igarashi, Y. Sasaki, M. Ogura, H.
Murai, S. Okamoto, M. Ogita, M. Kasai, T. Kobayashi, N. Ishizuka, S.
Takashima, M. Shimoyama, K. Tobinai and the members of the
JCOG. Department of Surgery, Tokai University School of Medicine,
Kanagawa 259-1193, Japan
Between May 1993 and March 1999, JCOG conducted a ran-
domized phase III study to evaluate the efficacy of HDC with
cyclophosphamide 6 g/m2 and thiotepa 600 mg/m2 as consolida-
tion in high-risk primary breast cancer. Pts below 56 years of age
with stage I to IIIB involving 10 or more positive axillary nodes
were eligible. A total of 97 were enrolled. The median age was 46
(range 27-55), and the median number of involved axillary nodes
was 16 (range 10-49). 48 pts in the standard treatment arm
received 6 courses of CAF (cyclophosphamide 500 mg/m2, adri-
amycin 40 mg/m2 and fluorouracil 500 mg/m2; q 3 weeks) fol-
lowed by tamoxifen. 49 pts were assigned to receive HDC with
autologous stem cell support after 6 courses of CAF followed
by tamoxifen; however, 15 pts (31%) in the HDC arm did not
receive HDC actually, including 7 recurrent breast cancer,
7 withdrawals and 1 ineligible. The HDC treatment was well tol-
erated without any treatment-related deaths. At 4 years, the
intent-to-treat RFS of 47 eligible pts in the standard arm and
48 eligible pts in the HDC arm was 43% (95% CI, 28-57%) and
61% (95% CI, 47-75%) (one-sided logrank, p = 0.12); overall
survival (OS) was 66% (95% CI, 52-81%) and 68% (95% CI,
54-82%) (p = 0.80), respectively. 
Conclusions: Although the statistical power in this study may
not be enough to detect marginal difference, no advantage of the
use of HDC in this setting was observed in RFS or OS.
High-dose chemotherapy (HDCT): adjuvant breast cancer
G. Rosti, U. De Giorgi, G. Papiani, P. Pedrazzoli, T. Demirer. On behalf
of the EBMT STWP. Department of Oncology and Hematology, Ravenna, Italy
In the last decade, several phase II studies and registries data
have shown a 55-65% disease-free survival for patients with high-
risk breast cancer at 4-5 years post transplant. As these data
appeared better than those obtained with standard-dose, several
groups launched phase III studies to address the question “Is more
better?”. One of the positive aspects of HDCT in the adjuvant
setting was the dramatic decline in toxic deaths (<1% in the
EBMT Registry) compared to previous experiences in the
metastatic setting. So far seven phase III trials have been pre-
sented (abstracts or full papers) and the results are going to be
highlighted at the Meeting. An irrational “door slamming” was
suggested by several oncologists, due to the fact that the results
have been considered as “negative”. But: 1) The standard arm is
not always a standard one (the Interscandinavian Study used
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9 courses of escalated FEC-which is high-dose itself). 2) CALGB
study has shown a never reached before 62% DFS @ 10 years for
both arms. 3) There is clear superiority for HDCT in the Dutch
Study for OS as well as for DFS. 4) Signiﬁcant DFS for HDCT
was obtained in the PEGASE 01 study. Meta-analysis may not be
the solution due to the heterogeneity of both experimental and
standard arms. “Slamming the door in 2002” will not let the scien-
tific community see what’s in next room. Two strategies are
ahead: complete ongoing studies and the taking into consideration
of possible novel aspects (i.e., high-dose dense concept).
Is there a role for low intensity transplantation in haema-
tological malignancies. Hype or hope.
R. Chopra. The Chrisite Hospital, Manchester, UK
The introduction of low intensity transplantation protocols in
patients with relapsed or resistant haematological cancers and in
some settings solid tumours such as renal cell cancer have been the
subject of a number of Phase I and II studies. There is no doubt
that the introduction of these regimens has signiﬁcantly increased
the number of patients who can safely receive these therapies.
Indeed some centres are undertaking these procedures in patients
up to 70 years. There is, however, a need to carefully deﬁne the
exact place for this approach in different subgroups of patients.
The main issues that will be covered in this presentation are:
1. Which disease and at what stage in the treatment programme
should non-myeloblative transplants be offered to patients?
2. Which is the optimal conditioning regimen?
3. What is the role of donor lymphocyte infusions?
4. What is the experiment basis for graft –v- leukaemia effect in
this setting?
5. How can current approaches be improved?
The UK Co-operative Group has undertaken low intensity
transplantation with Fludarabine, Melphalan and CAMPATH1-H
in over 120 patients with haematological malignancy. Using this
approach their treatment related mortality is low (12% at 100 days
with an actual probability of treatment related mortality at
8 months of 28%). The main problems associated with this
approach being the high incidence of CMV viraemia but with the
use of pre-emptive therapy mortality rate was low. The incidence
of Grade 3 for graft-v-host disease was only 4% and although the
incidence of chronic graft-v-host disease increased with the use of
donor lymphocyte infusions. Matched unrelated donor transplants
have been undertaken in 48 patients (aged between 18 and
62 years). A mismatch at one HLA locus was present in 21 out of
48 donors. Despite this, graft failure was only seen in 2 out of
48 recipients. There were 7 out of 48 early deaths and 3 later
deaths (>100 days). The actuarial 1 year survival was 72%. These
data indicate that low intensity transplantation can be undertaken
relatively safely even with an unrelated donor in an older age
group. However, longer follow up is necessary to ascertain long
efficacy. Alternative approaches such as autologous stem cell
transplantation or intensive chemotherapy need to be compared
with the low intensity approach before their place can be deﬁned
in routine clinical practice. This presentation will also compare
the different low intensity regimens being used at different cen-
tres. The role of CAMPATH1-H and the place of donor lympho-
cyte infusions in this setting remains to be defined and the UK
experience in 62 patients will be presented.
Targeting Her2/Neu+ breast, prostate cancer, and pancre-
atic cancer using armed activated T cells
L. Lum. Roger Williams Cancer Center, Providence, RI and Boston University,
Boston, MA, USA
Anti-CD3 activated T cells (ATC) can be infused safely after
high dose chemotherapy and stem cell rescue in patients with
stage IV breast cancer without dose limiting toxicities. However,
in order to improve the cytotoxicity of T cells, we armed ATC
with anti-CD3 x anti-HER2/neu BiAb (Her2Bi) to target
Her2/neu+ tumors. ATC armed with Her2Bi bind to T cells and
HER-2/neu on tumors. ATC armed with BiAb aggregate with
and lyse HER-2/neu+ breast, prostate, and pancreatic cancer cell
lines. Speciﬁc cytotoxicity increased with increasing arming doses
and effector to target ratios. BiAb persists on ATC for 3 days and
kill for more than 2 days. Armed ATC from normal subjects and
cancer patients markedly enhanced the speciﬁc cytotoxicity at the
various targets and the amounts of IFNγ, TNFα, and GM-CSF
secreted when armed ATC were exposed to Her2/neu+ tumor cell
lines. Studies in Beige/SCID mice show that established tumors
can be ablated using multiple injections of armed ATC. FDA-
approved Phase I/II clinical trials have begun for the treatment of
hormone refractory prostate cancer (armed ATC alone) and stage
II-III with ≥4 positive nodes, or stage IV breast cancer. The infu-
sions of armed ATC in prostate and breast cancer patients have
been safe. This approach of arming ATC with BiAb provides a
efficient, cost-effective method for producing large numbers of
antigen-speciﬁc cytotoxicity T lymphocytes.
Natural killer cell based cellular immunotherapy
H. Klingemann. RUSH Medical School, Chicago, IL, USA
Natural killer (NK) cells are part of the innate immune system.
In contrast to T-cells, their action against “invaders” is immediate,
not requiring sensitization or priming. They destroy infected and
transformed cells through secretion of perforin which prepares the
tumor cell membrane for the entry of proteinases (granzymes)
that degrade the DNA of the target cell. NK cells carry the CD56
antigen and are negative for the CD3 marker in contrast to NK-T
cells, which express both markers. Murine studies have demon-
strated the anti-tumor effect of NK cells and its cytokine (IL-2)
activated form, generally termed activated NK (ANK) cells.
Treatment protocols with NK or ANK cells in patients with can-
cer are sparse and, not surprsingly, have not shown a clear anti-
tumor effect. Initial clinical trials by Rosenberg et al. had used
LAK cells, which represent polyclonal T-cells with only 10%
NK-cells. New indications for NK-cell therapy are emerging.
NK/ANK cells express the Fcγ receptor (CD16) which binds to
the Fc component of monoclonal antibodies and mediates anti-
body dependent cellular cytotoxicity (ADCC). Recent studies have
shown that some monoclonal antibodies destroy malignant cells
predominantly through ADCC. Studies are now underway to test
if the concomitant infusion of autologous NK cells and mono-
clonal antbodies enhances the anti-tumor efficacy of these anti-
bodies further. Allogeneic NK cells on the other hand seem to
play a role in suppressing graft-versus-host disease after stem cell
transplantation and at the same time mediate an anti-tumor effect.
A separation process/devise for human autologous/allogeneic NK
cells has been approved in Europe but not yet by the FDA. How-
ever, the allogeneic ANK cell line NK-92 has entered phase I
trials in Europe and the US. NK-92 lack killer cell inhibitory
receptors (KIR) and kill a broad spectrum of malignant cells more
effectively than blood ANK. NK-92 cells can be grown in large
quantities under serum free conditions according to GMP guide-
lines. The phase I study in Europe has accrued 8 patients so far,
none of whom experienced any side effects. The study in the US
has been approved for treatment of patients with melanoma and
renal cell cancer. In addition an “in the bag” purging protocol is
underway in low grade lymphoma. NK have long been ignored as
a therapeutic cell product. This is changing as we discover the
complexity of these cells, their distinctiveness from T-cells and
their potential in clinical applications.
Minor histocompatibility (H) antigens in graft versus
tumor responses and GVHD
S. Riddell. Fred Hutchinson Cancer Research Center
Immune-mediated elimination of tumor cells by donor T cells
recognizing recipient minor H antigens contributes to the curative
potential of allogeneic HCT. The importance of the allogeneic
response to a successful outcome is clearly illustrated by the
results of stem cell transplant for malignancy after nonmyeloabla-
tive conditioning. Remarkably little is understood about the
molecular nature of minor H antigens and this has impeded
efforts to determine the role of speciﬁc disparities in graft versus
tumor reactions or to manipulate T cell responses to augment
antitumor activity without exacerbating GVHD. The isolation of
minor H antigen-specific CD8+ and CD4+ T cell clones from
recipients of allogeneic HCT has provided the reagents to charac-
terize their expression on leukemic progenitors and to identify the
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genes encoding these antigens. Using cDNA expression cloning,
genetic polymorphisms in the human IFI-75, Uty, and KIAA0020
genes have been identiﬁed to encode new minor H antigens pre-
sented by HLA A3, B8, and A2 respectively. Two of these genes
are preferentially expressed in hematopoietic cells including
leukemic progenitors suggesting it may be possible to augment
T cell responses to promote a selective graft versus leukemia
effect. The studies to identify the molecular nature of minor H
antigens have provided insights into the complexities of the graft
versus host response associated with allogeneic HCT, but the
challenge for the future will be to develop strategies that can
selectively induce durable graft versus tumor effects without
GVHD. A critical issue in developing speciﬁc immunotherapy to
augment GVL responses is to determine which minor H antigens
are expressed on leukemic stem cells. Studies using transplantation
of human AML into SCID mice have identified a putative
leukemic stem cell which is contained in the CD34+ CD38– subset
of the blast population and is present in very low frequency
(<1/200,000) in blood or bone marrow from AML patients. We
have examined the ability of minor H antigen-specific CTL to
prevent engraftment of human AML in NOD/SCID mice. These
studies show that engraftment of leukemias derived from individu-
als encoding the minor H antigen can be specifically prevented
demonstrating that AML stem cells express minor H antigens and
are targets for CTL. One approach to determine directly which
minor H antigens can be selectively targeted to induce a GVL
effect without GVHD is to adoptively transfer T cell clones of
defined specificity and function to patients who relapse after
HCT. Studies of this approach are now in progress in acute
leukemia and have provided important insights into potential
obstacles of T cell therapy for relapsed leukemia after HCT.
In vivo purging and consolidative immunotherapy with
Rituximab can induce high frequency of molecular remis-
sion in patients undergoing high dose therapy and stem
cell transplantation for low grade or mantle cell non-
Hodgkins lymphoma
N. Berinstein. Advanced Therapeutics Program, Toronto Sunnybrook Regional
Cancer Centre, Canada
The management of patients with recurrent indolent lymphoma
or newly diagnosed mantle cell lymphoma needs improvement.
Although high dose therapy and stem cell transplantation can
induce long remissions, unfortunately a continued pattern of
relapses has been documented in both of these diseases. We have
attempted to improve the outcome of high dose therapy and stem
cell transplantation in these diseases by incorporating Rituximab
both as an “in vivo purge” and consolidative immunotherapy. We
have transplanted 18 patients with recurrent follicular lymphoma
and 14 patients with newly diagnosed mantle cell lymphoma. Sev-
enteen of the follicular lymphoma patients entered a complete
response (CR) or CRu (undeﬁned) and all of the mantle cell lym-
phoma patients achieved a CR or CRu after transplant. With a
median follow up of approximately two years, only one patient
with follicular lymphoma has relapsed and one patient with man-
tle cell lymphoma died of an unrelated cause. Molecular diagnos-
tics have been performed in 13 of the follicular lymphoma patients
and 11 of the mantle cell lymphoma patients with diagnostic
translocations or immunoglobulin rearrangements. Whereas all
patients have molecular markers of their disease in the peripheral
blood and/or bone marrow prior to initiation of therapy, only one
of the follicular lymphoma patients has detectable disease in the
peripheral blood and bone marrow in follow-up, up as long as 36
months post transplant. Nine months post transplant, 5 of 7
patients with mantle cell lymphoma are in molecular remissions.
We were unable to successfully purge the stem cell grafts with the
Rituxan in vivo purge but despite this, patients achieved molecular
and clinical remissions, suggesting that Rituximab consolidative
immunotherapy may be effective in eliminating minimal residual
disease or that lymphoma cells contaminating the graft were not
viable. These results compare favorably to high dose therapy and
stem cell transplantation results using more conventional ex vivo
purging. Further follow up is required to determine whether
incorporating Rituximab into high dose therapy and stem cell
transplantation for low grade non-Hodgkins lymphoma is worthy
of further investigation and randomized studies.
Feasibility of a five-step strategy to improve outcomes
for autologous stem cell transplants for hematologic
malignancies
G. Elfenbein. Blood and Marrow Transplant Program, Roger Williams Cancer
Center, Providence, RI, USA
In 1998, we initiated a strategy to improve outcomes for
patients (pts) with hematologic malignancies. The strategy has
five steps: 1. Increased intensity of disease specific, induction
therapy (maximal cytoreduction). 2. Mobilization of blood stem
cells with chemotherapy and growth factor for fastest recovery of
neutrophils (cyclophosphamide [CY], prednisone and G-CSF).
3. Positive selection of CD34+ cells (purging graft of tumor).
4. High dose therapy with known effective regimen (disease spe-
ciﬁc but with lowest known toxicity). 5. Consolidation with dis-
ease speciﬁc immunotherapy (treating minimal residual disease).
Here we report the ﬁrst 18, consecutive pts who were transplant
eligible and are in or have completed the 5th step. Among the
pts were 10 with non-Hodgkin’s lymphoma (NHL), 1 with
Hodgkin’s disease (HD), and 7 with multiple myeloma (MM).
Only 5 (28%) would be considered to be good prognosis pts (ﬁrst
CR of NHL or first PR of MM). Only 7 (39%) had sufficient
CD34+ cells collected to allow positive selection. The 11 lym-
phoma pts (63%) received CY-thioTEPA-carboplatin and the
7 MM (37%) received 3 cycles of melphalan (Exp Hematol 28
(Suppl. 1): 87, 2000.) Neutrophil recovery was prompt in 16 pts
(89%). Lymphoma pts received involved field irradiation for
residual masses or history of bulky disease. One patient (5.5%)
refused immunoconsolidation therapy after completing irradia-
tion for HD. The 12 pts (67%) whose disease was CD20 positive
(2 with MM and 10 with NHL) received all four planned weekly
doses of antiCD20 monoclonal antibody (Rituxan®). Five of the
7 MM pts (71%) were started on alpha-interferon but only 2
(40%) tolerated chronic administration. With a median follow-up
of 15 months there have only been 4 pts (22%) who developed
disease progression. There have been 6 deaths (33%), 4 from
progressive disease (22%) and 2 from late, TMP-SMX resistant
pneumocystis pneumonia (11%). It is feasible to incorporate
immunoconsolidation into the treatment strategy but ultimate
long-term disease free outcome remains to be determined.
HER-1 and HER-2
E. Perez. MayoClinic, Jacksonville, FL, USA
The epidermal growth factor receptor family of proto-oncogenes
is known to be clinically relevant for a variety of human malig-
nancies, including breast cancer. This family of genes encodes
four structurally related transmembrane receptor tyrosine
kinases: the epidermal growth factor receptor (EGFR, ErbB,
HER1), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4).
Cross talk and heterodimerization of the members of this family
lead to a variety of downstream signal transduction steps. Thus,
although no soluble ErbB2 ligand has been identified, ligand
binding to the other members of the ErbB family induces recep-
tor heterodimerization and activation of ErbB2. Overexpression
of ErbB2 has been associated with an aggressive tumor pheno-
type, both in pre-clinical and clinical studies, and to confer differ-
ential sensitivity to various treatment approaches. Optimal meth-
ods to test for overexpression and/or ampliﬁcation of member of
this family are ongoing. Trastuzumab can be cited as a prototype
for rationally designed antineoplastic drugs that target HER2.
The activity and overall therapeutic ratio of this agent, alone or
with chemotherapy, have led to regulatory approval for use in
many countries around the world. Essentially, the only signiﬁcant
adverse effect of this agent to date has been what appears to be
cardiac toxicity. This toxicity is mostly observed in patients
receiving concurrent doses of anthracyclines >300mg/m2; a vari-
ety of pre-clinical and clinical trials are ongoing to better under-
stand its pathophysiology and management. Four worldwide clin-
ical trials are now evaluating the role of this targeted therapy in
patients with HER2 + breast cancer eligible to receive adjuvant
systemic treatment N9831, B-31, BCIRG006, HERA. A variety
of targeted therapies directed at ErbB1 are in clinical trials, either
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as small molecule inhibitors or monoclonal antibodies. Some of
these agents include ZD1839, OSI-774, and C225, amongst oth-
ers. Pre-clinical and clinical trials exploring the use of these
agents alone or in combination with other agents currently in use
to manage patients with breast cancer are being developed or are
active. Exploration of the therapeutic ratio of these agents along
with studies of molecular predictors for response/toxicity will be
of signiﬁcant value to patients with breast cancer.
HER-2/neu testing: an update
W. Hanna. Department of Anatomic Pathology, Sunnybrook and Women’s Col-
lege Health Sciences Centre, Toronto, Ontario, Canada
The predictive and prognostic significance of amplification/
overexpression of the Her2/neu gene has been well established.
This has resulted in significant increase in testing for the
Her2/neu status of breast cancer in laboratories across the world.
The different methodologies used and the availability of numer-
ous antibodies/molecular probes with variable speciﬁcity and sen-
sitivity has resulted in confusion as to what would be the best
methodology that will provide accurate clinical assessment of the
Her2/neu status of a given breast tumor. The most commonly
used methodology which are practical to use in a diagnostic
pathology laboratory are immunohistochemistry and fluorescent
in-situ hybridization (IHC and FISH). In order to validate any
testing methods, comprehensive technical and clinical validation is
required. Some clinical studies have advocated that FISH should
be the gold standard. In my presentation I will discuss the advan-
tages and disadvantages of IHC and FISH methodologies. I will
also report on the Canadian attempt to produce a testing algo-
rithm using the most current information from the literature.
This will be compared to other algorithms used in other parts of
the world. I would hope that this presentation will bring to the
audience an up-to-date review on Her2/neu testing methodolo-
gies and an update on the Canadian testing algorithm.
Investigating the graft-versus-tumor effect in renal cell
carcinoma following non-myeloablative allogenic periph-
eral blood
R. Childs. Department of Hematology Branch, National Heart, Lung, and Blood
Institute, NIH, Bethesda, MD, USA
Since 1998, NIH has been conducting a pilot trial investigating
for GVT effects following nonmyeloablative allogeneic SCT in
patients with advanced RCC. Fifty-two patients with metastatic
and progressive RCC, most of whom had failed prior cytokine
based immunotherapy, were conditioned with cyclophosphamide
and ﬂudarabine then were transplanted with a G-CSF mobilized
blood stem cell allograft. Of 47 evaluable patients, 22 (47%) had
partial (n=18) or complete (n=4) regression of metastatic disease
consistent with a GVT effect. A mixed response was observed in
6 (10%) additional patients. Regression of metastatic tumor was
1) delayed a median of 6-mths (range 1-13 mths) following trans-
plant, 2) usually followed CSA/MMF withdrawal, 3) occurred
after a donor lymphocyte infusion in 5 patients, 4) was favorably
associated with a history of graft-versus-host disease (GVHD),
and 5) typically did not occur until T-cell chimerism had transi-
tioned from mixed to predominantly donor. The immune media-
tors contributing to the GVT effect in RCC are currently under
investigation. We have successfully generated donor CD8+
T-cell clones from lymphocytes obtained from responding
patients that have direct cytotoxicity against the patient’s RCC
cells (obtained prior to transplantation). Although some of these
T-cell clones recognize tumor alone, as determined by interferon
gamma secretion, and cytotoxicity, many recognize both patient
tumor and patient hematopoietic cells. Interestingly, in one
patient who had disease regression associated with acute GVHD,
we were unable to expand tumor specific T-cell populations at
the time of disease regression but were able to expand a number
of 14 different CD8+ T-cell clones which recognized both autol-
ogous EBV transformed B cells and patient RCC cells, strongly
implicating mHa’s as being the target for a GVT effect in this
patient. The target antigens of these tumor reactive T-cells have
not yet been determined.
Targeted therapeutics phase I trials
K. Gelmon. Cancer Research Centre Department of Advanced Therapeutics,
Vancouver, BC, Canada
Novel targeted agents are being developed in the laboratory
and introduced into the clinic. This is challenging clinical
researchers to examine how we conduct phase I trials and evalu-
ate new drugs. The old paradigm of maximum tolerated dose
(MTD) and deﬁning dose by toxicity is being questioned. Is the
top and toxic dose the most effective or do we need to deﬁne the
minimum inhibitory dose (MID) for these agents? To define a
MID we need to measure target effect and this is often difﬁcult in
the clinical setting. Direct target effect often requires repeated
biopsies, which are not possible in the majority of patients.
Neoadjuvant phase I studies are a source of pathological material
but often raise ethical issues. Surrogate target effects may be used
to assess the activity of an agent but need to be validated and this
may pose technical difﬁculties and ambiguity. Increasingly we are
being asked to show biological effect in the Phase I trial as the
decision to proceed with developing the agent is being made ear-
lier in clinical development. As well, there are questions of
chronic dosing and how can we deﬁne this in terms of our phase I
strategies. These issues will be discussed in the talk and will be
highlighted using a number of recently completed or ongoing
Phase I studies including studies of antisense agents, small mole-
cules, farnesyl transferase agents, and anti-angiogenesis studies. It
is imperative that we rapidly and creatively define new Phase I
strategies, which are acceptable to researchers, patients, pharma-
ceutical companies and regulatory bodies.
Targeted therapeutics: Farnesyl-transferase inhibition
A. Grothey. Department of Hematology and Oncology, University of Halle, Germany
Some of the most frequently observed oncogene alterations are
mutations in the ras oncogene family that occur in approximately
30% of all human malignancies. Each mammalian cell contains at
least three different ras proto-oncogenes (k-, h- and n-ras) that
encode distinct membrane-localized G proteins of 21 kD. These G
proteins play a pivotal role in transducing biological information
from the cell surface to the nucleus. Activating mutations in Ras
proteins result in constitutively active signaling thereby stimulating
cell proliferation and inhibiting apoptosis. Inhibition of Ras-signal-
ing has been the focus of various experimental approaches as anti-
cancer treatment in recent years. The most important approaches
are the prevention of membrane localization (and thus activation)
of Ras by Farnesyl Transferase Inhibitors (FTIs); the inhibition of
Ras protein expression by ribozymes or antisense strategies; and
the inhibition of downstream effectors of Ras function. FTIs have
emerged as the most promising Ras-inhibiting agents. Based on
their method of action FTIs can be subdivided into three different
groups: 1.) CAAX competitive inhibitors thast compete with the
CAAX portion of Ras for binding to FT; 2.) farnesyl-pyrophos-
phate (FPP) competitors that compete with the subtrate FPP for
FT; and 3.) bisubstrate inhibitors. Four different FTIs are cur-
rently in clinical trials in various solid tumors and hematological
malignancies. Clinical activity has been demonstrated in several
diseases. The review will give an overview of the latest results of
clinical trials on Ras inhibition focusing on the safety proﬁle, efﬁ-
cacy and perspectives of FTIs as anti-cancer agents.
Hematopoietic growth factors
G. Lyman. The Cancer Centre of Albany Med., Albany Medical Center, Albany,
NY, USA
Myelosuppression with neutropenia and its associated compli-
cations including febrile neutropenia (FN) remain the major
dose-limiting toxicities associated with High Dose Chemother-
apy. The incidence of FN varies considerably with treatment
regimen as well as patient age and various co-morbid conditions.
Randomized controlled trials (RCTs) in both North America
and Europe have demonstrated granulocyte-colony-stimulating
factor (G-CSF; filgrastim) administered prophylactically follow-
ing systemic chemotherapy to be both efficacious and safe. A
recent meta-analysis of the published RCTs has demonstrated
that prophylactic G-CSF reduces the frequency of FN and docu-
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mented infections as well as the need for dose reductions and
treatment delays for a variety of disease entities and treatment
regimens. Economic analyses have demonstrated that G-CSF
support of cancer chemotherapy can actually reduce cost in
patients at moderate risk of FN. Guidelines have been developed
and recently updated by the American Society of Clinical Oncol-
ogy (ASCO) for the use of the hematopoietic growth factors.
Recent interest has focused on the ability of these agents to
enable patients with responsive and potentially curable malig-
nancies to facilitate the delivery of full dose intensity in patients
with responsive and potentially curable malignancies. An addi-
tional important area of research includes the development and
validation of clinical prediction models for risk of FN or reduced
dose intensity in order to enhance the cost-effective application
of the hematopoietic growth factors. Finally, a long acting pegy-
lated formulation of filgrastim (Pegfilgrastim; Neulasta) has
recently been developed and approved by the US FDA. The
addition of a 20 kD polyethylene glycol to the N-terminus of the
filgrastim results in a molecule with a extended serum half-life
and duration of action. Pegfilgrastim has similar neutrophil
receptor competitive-binding affinity for the G-CSF receptor as
filgrastim increasing neutrophil numbers and function. In a self-
regulating fashion, pegfilgrastim remains in the circulation dur-
ing periods of neutropenia and then is cleared rapidly by recep-
tor binding during neutrophil recovery. In two pivotal RCTs in
breast cancer, a single injection of pegfilgrastim was found to be
equally effective to standard daily filgrastim in terms of the dura-
tion of neutropenia but was actually found to be more potent in
reducing the risk of FN. The introduction of pegfilgrastim
therefore appears to offer several advantages including once-
per-cycle and perhaps fixed dose treatment, greater compliance,
improved quality-of-life due to fewer physician visits and injec-
tions and equal safety with possibly greater potency. Neutrope-
nia and its complications remain major limitations of cancer
chemotherapy but new strategies and agents offer greater oppor-
tunities for improved patient care and quality of life.
High dose chemotherapy (HDC) with autologous hemo-
poeitic cell support for advanced ovarian cancer in 1st
complete remission: retrospective analysis from Solid
Tumor Registry of the European Group for Blood and
Marrow Transplantation
C.Bengala,1 V.Guarneri,1 J.Ledermann,2 H.Wandt,3 H.Lotz,4
J.H.Cure,5 G.Rosti,6 P.Ferrante,6 T.Demirer,7 P.F. Conte,1 on behalf
of the Solid Tumour Working Party of the EBMT. 1Division of Medical
Oncology, St. Chiara University Hospital, Pisa; 6Division of Medical Oncology,
City Hospital, Ravenna, Italy; 2Dept. of Oncology, UCL, London, UK; 5Centre
Jewan Perrin, 4Clermont-Ferrand, Hopital Tenon, Paris, France; 3BMT Unit,
Medical Klinik, Nuremberg, Germany; 7Dept. Hematology/Oncology, University
Medical School, Ankara, Turkey
Despite the high response rate, patients (pts) with advanced ovarian
cancer have a poor long-term prognosis. HDC has showed a signiﬁ-
cant beneﬁt in pts in remission. We performed a retrospective analy-
sis on 77 pts with ovarian carcinoma in 1st CR treated with HDC and
hemopoietic support from 20 centers of EBMT group. Median age
was 48 years (range 15-64). After surgery, 14 pts had no residual dis-
ease (RD), 24 pts <2 cm, 19 pts >2 cm. After induction chemotherapy
(CT) 14 pts were in pCR, 8 pts had microscopic RD, and 40 pts were
in cCR. Fifty-one pts received a single course of HDC; 26 pts
received multiple cycles of HDC (2-5). Hemopoietic stem cell sup-
port was bone marrow in 21% and peripheral blood in 79% of the
pts. Median follow up was 4 years (range 0.5-11). Median time to
progression (TTP) and overall survival (OS) of all patients were 19.4
and 46.5 mos respectively. According to RD after surgery, median
(95% CI) TTP and OS for pts with no RD have not yet been
reached: at 8 years, PFS and OS are 52% and 73% respectively.
Median TTP for pts with RD <2 cm and >2 cm were 13,5 and 24,7
mos respectively; median OS was 46,1 and 41.2 mos respectively.
(p:NS). According to the disease status before HDC, median TTP
and OS were 26.8 and 45.8 mos for pts in pCR, 24 and 35 mos for pts
with microscopic disease, 16 and 49 mos for pts in cCR (p: NS).
Median TTP for pts receiving single vs multiple cycle of HDC was
19 and 27 mos respectively (p:NS); median OS was 46,4 and 45,8
mos respectively (p:NS). Tumor grade, source of stem cells and type
of cytokine (G-CSF vs. GM-CSF) had no impact on TTP and/or
OS. In conclusion these data show interesting long-term progression-
free and overall survival rates after high-dose consolidation therapy in
advanced ovarian cancer in complete response (clinical or pathologi-
cal) after induction CT. Due to the limited number of pts no prog-
nostic factor has shown a signiﬁcant impact on survival.
Immunotherapy with gene expression profiled IL2 or IL7
transfected Ewing tumor cells in NOD/SCID mice
S. Burdach, G. Baersch, M.S. Staege, G. Hanse. Children’s Cancer
Research Center and Laboratory of Immunology and Transplantation Biology, Bio-
Center, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany
Ewing Tumor (ET) is a systemic malignancy characterized by
expression of unique ews/ets fusion genes. The resulting chimeric
transcription factors represent candidate tumor speciﬁc antigens.
Although more than half of the patients with localized manifesta-
tion of the disease can be cured with current multi-modality
regimens, cytotoxic chemo/radio-therapy has still not yielded sat-
isfactory results for patients with most advanced disease. However,
some evidence suggests, that cytokine therapy may improve the
prognosis in a subset of patients. 
Objective: To assess immunogene therapy in ET we stablely
transfected ET cells with a vector containing the cDNAs for IL-2
or IL-7 and tested the immunostimulatory and therapeutic poten-
tial of the irradiated cells in our previously established NOD-
SCID mouse ET model. As the homogeneity in gene expression
and peptide presentation amongst various native tumors is a pre-
requisite of any efficacious immunogene therapy utilizing allo-
geneic cells as well as tumor specific peptides, we have also
assessed gene expression proﬁles in native Ewing tumor samples
and wild type (wt) and transgenic cell lines utilizing optimized
high density microarray analysis. 
Methods: wt and irradiated IL-transfected ET cells were co-
transferred with HLA matched human mononuclear cells
(PBMCs). Control mice received mock-transfected instead of
IL-transfected ET cells. For gene expression analysis, we
employed a custom chips containing 35.402 probe sets for approx.
20.000 genes on a single chip comparing wt and transgenic ET cells. 
Results: Vaccination with irradiated IL-2-transfected ET cells sig-
niﬁcantly reduced wt tumor growth in NOD-SCID mice as com-
pared to controls. A signiﬁcant anti-tumor effect was also observed
after vaccination with irradiated IL-7 transfected ET cells. Both IL-2
and IL-7 transfected ET cells increased and activated T cells and NK
cells in vitro: number and ﬂuorescence intensity of CD25-positive
and CD56-positive cells signiﬁcantly increased after co-culture of wt
with IL-2 or IL7 transfected ET cells and primed human PBMCs.
Moreover, co-culture with IL-2 but not with IL7-tranfected ET cells
almost completely supressed wt ET cell growth in vitro while there
was no suppression by mock-transfected cells. Side effects in the
treated animals were not observed. Gene expression analysis revealed
that allogeneic cell lines and native tumors displayed a substantial
degree of homogeneity of geneexpression in Ewing Tumor. 
Conclusion: From this data in the NOD-SCID model we con-
clude that gene expression profiling may reveal a substantial
degree of homogeeity between cell lines used as vaccines and and
native tumors. Moreover, gene therapy with IL-2 or possibly IL-7-
transfected irradiated ET cells may have therapeutic potential for
patients who suffer from this aggressive neoplasia.
High Dose Therapy for patients with primary multifocal
and early relapsed ewing tumors: results of two consecu-
tive regimens in the Meta-EICESS study
S. Burdach, R. Haase, A.Meyer-Bahlburg, H.J. Laws, B. Metzner, O.
Diwan, A. Wawer, R. Finke, J. Dunst, H. Juergens. For the International
Meta-EICESS Study Group, Coordinated at Departments of Pediatric Hematol-
ogy/Oncology, Pediatric Surgery and Radiation Oncology, Martin Luther Univer-
sity School of Medicine, Halle/Saale, Germany
Risk stratiﬁcation of metastatic and relapsed Ewing Tumors (ET)
has been a matter of debate during the last decade. To date, data
show that patients with bone or bone marrow metastases have a
poorer prognosis than patients with primary lung metastases. In addi-
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tion, early (≤24 months after diagnosis) or multiple (≤2) relapses carry
a poorer prognosis than late relapse (>24 months after diagnosis).
Taken together, these patients constitute the worst risk group in
Ewing Tumors. Few (<5%), if any patients with these high risk fea-
tures have survived their disease before the era of high dose chemora-
diotherapy (HDC) and stem cell transplantation (SCT). Objectives:
The results of the present Meta-EICESS protocol were compared to
the previous Hyper-ME study, both at 5 years, in a patient popula-
tion within the same high risk stratum. Methods: In the Hyper-ME
study, we utilized 2 × EVAIA for systemic induction, 2 × EVAIA for
stem cell apheresis, 2 × EVAIA combined with involved compart-
ment irradiation and SCT for local intensiﬁcation and ﬁnally mye-
loablative systemic consolidation with hyperfractionated total body
irradiation (hfTBI) combined with Melphalan/Etoposid followed by
SCT (HyperME protocol). In the present Meta-EICESS protocol
identical induction and local intensiﬁcation strategies were used with
the exception that VIDE chemotherapy was employed instead of
EVAIA; in addition, Tandem (2×) ME plus SCT was used for sys-
temic intensiﬁcation. 26 patients were enrolled in Hyper-ME and 28
patients in Tandem-ME. Results: EFS in Hyper-ME was 25±10%
and 27±9% in Tandem-ME. In Hyper-ME the prognosis for
patients ≥17 years of age was 0% as compared to 36±10% for patients
<17 years, whereas EFS for patients <17 years vs. >17 years was not
different in Tandem-ME. In addition, death of complication (DOC)
rate was 19% in Hyper-ME and 4% in Tandem-ME. Conclusions:
Meta-EICESS offers a decent, albeit still not satisfactory rate of long
term remissions in most advanced stage ET with short term treat-
ment. In particular, the prognosis for patients older than 17 years has
been improved from 0 to 24±10% with Tandem-ME. Future studies
are necessary to identify novel treatment modalities for this high risk
group of patients with ET.
Results of high-dose chemotherapy followed by autolo-
gous stem cell transplantation without radiation in
5 patients with primary CNS lymphoma associated with
poor prognostic features
T. Cheng, P. Forsyth, D. Morris, S. Glück, C. Brown, J.A. Russell,
and D.A. Stewart. Department of Medicine and Oncology, University of Cal-
gary and Tom Baker Cancer Centre, Calgary, Alberta, Canada
In order to avoid the neurotoxicity associated with combined whole
brain radiotherapy (WBRT) and MTX-based chemotherapy and to
avoid the high relapse rates associated with either modality alone, we
treated a small series of patients with HD-MTX/Ara-C induction
therapy followed by HD thiotepa, busulfan, cyclophosphamide, and
autologous stem cell transplant without WBRT for primary CNS
lymphoma (PCNSL). Between 1998 and 2000, 5 patients with poor
prognosis PCNSL all received induction chemotherapy with MTX
and Ara-C. One patient went on to receive HD-BEAM and ASCT as
part of a competing study. He obtained a complete remission but
relapsed 7 months later. He then received TBC/ASCT as the only
salvage treatment without any re-induction therapy. He continues in
second CR now 32 months after diagnosis and did return to work.
Three other patients were not eligible for the competing protocol
because of a KPS of 30%, while the ﬁnal patient was treated after the
competing protocol was closed. Of our ﬁve patients, there was one
transplant related fatality and one CNS recurrence at 28 months
post-ASCT. The three others are currently in CR ranging 15 to 27
months from diagnosis. In conclusion, prolonged CR is possible after
chemotherapy-only protocol for PCNSL, even for patients who are
profoundly disabled at diagnosis or have relapsed disease. This proto-
col is associated with minimal neurotoxicity and improvement in neu-
rological function. HD chemotherapy for PCNSL should include
drugs that penetrate the CNS extremely well such as busulfan and
thiotepa rather than standard lymphoma regimens such as BEAM.
Mobilization of peripheral blood stem cells (PBSCs) with
chemotherapy and recombinant human granulocyte-
colony stimulating factor (Rh-GSCF): A randomized evalu-
ation of different doses of Rh-GSCF
T. Demirer,1 M. Ayli,1 M. Dagli,2 S. Dincer.1 1Ankara Numune Hospital
and 2Ankara Oncology Hospital
To date, there is no randomized study comparing different doses
of rhG-CSF following mobilization chemotherapy (MC). There-
fore, in this study the effect of different doses of rhG-CSF follow-
ing MC on yields of CD34+ PBSCs were evaluated. Fifty patients
were randomized to receive rhG-CSF 8 (n = 25) versus 16 (n = 25)
µg/kg/day following MC. The median number of CD34+ cells
collected after 8 µg/kg/day of rhG-CSF was 2.36 × 106/kg as com-
pared to 7.99 after 16 µg/kg/day (P < 0.001). Twenty of 25 (80%)
patients in the low dose and 23 of 25 (92%) in the high dose rhG-
CSF arm underwent autologous stem cell transplantation. Median
days of WBC engraftment in patients mobilized with 8 µg/kg and
16 µg/kg of rhG-CSF were 12 and 9, respectively (P < 0.001). But
there was no difference between 2 groups regarding the other
parameters of peritransplant morbidity such as days of platelet
engraftment (P = 0.10), RBC (P = 0.56) and platelet transfusions
(P = 0.22), days of TPN requirement (P = 0.84), days of fever (P =
0.93) and days of antibiotics (P = 0.77). These data showed that
higher doses of rhG-CSF following a MC were associated with a
clear dose response effect. Eight µg/kg/day is as effective as
16 ug/kg/day except a rapid neutrophil engraftment in the high
dose arm. Therefore, higher doses of rhG-CSF may not be used
for PBSC collections following chemotherapy based mobilization
regimens in this cost-conscious era.
Influence of post-transplant recombinant human granulo-
cyte-colony stimulating factor (RhG-CSF) administration on
peritransplant morbidity (PTM) in patients undergoing
autologous stem cell transplantation (ASCT)
T. Demirer,1,2 M. Aylı,1 M. Daglı,3 G. Ozet.1 Ankara Numune Hospital-
Ankara,Turkey
This study was performed to evaluate the effect of post-transplant
rhG-CSF on the parameters of PTM. Three sequential and con-
secutive cohorts of 20 patients each received either post-transplant
rhG-CSF at a dose of 5 µg/kg/day IV in the morning started on
day 0, day 5, or no rhG-CSF. Engraftment kinetics and other
parameters of PTM such as transfusion and TPN requirements,
fever, antibiotic administration as well as hospital stay were evalu-
ated with univariate and multivariate analysis. Patients receiving
post-transplant rhG-CSF starting on day 0 and 5 recovered gran-
ulocytes more rapidly than those not receiving post-transplant
rhG-CSF (P = 0.000 for ANC ≥ 0.5 and 1 × 109/L). Post-transplant
rhG-CSF starting on day 0 and 5 were significantly associated
with a decreased duration of fever (P = 0.002 and 0.001, respec-
tively) and antibiotic administration (P = 0.000 and 0.006,
respectively) compared to reference group of without rhG-CSF.
Post-transplant rhG-CSF was also signiﬁcantly associated with a
short hospital stay compared to reference group of without rhG-
CSF administration (P = 0.000 and 0.001, respectively). There was
also no difference between day 0 and day 5 arms regarding the
parameters of PTM. Post-transplant rhG-CSF is associated with a
faster granulocyte recovery and shortened duration of hospitaliza-
tion, fever as well as nonprophylactic antibiotic administration in
patients who receive ASCT.
The EBMT Solid Tumors Working Party (STWP) registry:
2001 report
T. Demirer, A.N. Kulekci. Ankara, Turkey
By November 2001, the EBMT has included 19,084 patients
with solid tumors, two thirds being female; mean age is 32.5 years
±18. Overall toxic death rate in 1991 was 6%, while in 2001 it was
reduced, to 2% (all ages, all diseases). Probably this may be due not
only to the universal use of PBPC in recent years, but to a better
patients’ selection and possibly, to an increased knowledge of the
procedure. Our working party has performed a survey to deter-
mine the future strategies in order to design new studies in patients
with high-risk primary and metastatic breast cancer with a ques-
tionnaire which was sent to transplant centers in the Europe.
Survey analysis will be announced during Montreux Meeting. For
limited SCLC and stage III-IV ovarian carcinoma, long-term dis-
ease free-survival is approaching 20% and 40%, but only the
results of the ongoing EBMT studies. We will be able to clearly
assess the role of autotransplantation over standard chemotherapy.
A new phase-I study was activated this year to investigate the efﬁ-
cacy of allogeneic mini-transplant in patients with refractory solid
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tumors. Also, a new phase-III study for platinum sensitive relapse
epithelial ovarian cancer will be activated in the beginning of 2002.
Detailed analyses are being carried out by several EBMT centers,
with the aim to hopefully provide possible prognostic factors as to
patients treated with high-dose chemotherapy for solid tumors.
A novel mobilizing regimen containing high-dose epiru-
bicin, preceded by dexrazoxane, paclitaxel and filgrastim
to support three courses of adjuvant high-dose dense
chemotherapy in patients with stage II-IIIa breast cancer
U. De Giorgi, G. Rosti, A. Zaniboni, G. Monti, P. Nicoletti, M.
Argnani, L. Sebastiani, M. Marangolo. Department of Oncology, General
Hospital, Ravenna, Italy
We designed a pilot adjuvant study of high-dose dense
chemotherapy (HDDC) with peripheral blood stem cells (PBSCs),
containing three courses with epirubicin 150 mg/m2, preceded by
dexrazoxane 1000 mg/m2, and paclitaxel 400 mg/m2, for patients
with stage II-IIIa breast cancer. In order to collect adequate
amounts of PBSCs, we assessed the mobilization capacity of high-
dose epirubicin 150 mg/m2, preceded by dexrazoxane 1000 mg/m2
(day 0), and paclitaxel 175 mg/m2 (day 1), plus ﬁlgrastim starting
24 hours after paclitaxel. The threshold fixed in our study was
>6 × 106 CD34+ cells/Kg b.w. Twenty-five patients have been
enrolled, median age 50 years (range 30-60). One patient went off
study due to a severe hypersensitivity reaction to paclitaxel.
Another patient presented fever persistent after hematological
recovery and was not admitted to leukapheresis procedure. In
23 patients, adequate number of PBSCs was collected by a single
leukapheresis. The median number of CD34+, CD34+/CD33-,
and CD34+/CD38- cells/Kg collected per patient was 17 × 106,
13.4 × 106, 1.5 × 106, respectively. Grade 4 neutropenia occurred
in 23/24 patients with a median duration of 3 days (range 1-5). No
grade 4 thrombocytopenia and grade 3-4 non-hematological toxi-
cities have been reported. Two patients needed red blood cell
transfusion. High-dose epirubicin, preceded by dexrazoxane for
the ﬁrst time used in mobilizing regimen, and paclitaxel plus ﬁl-
grastim are effective in releasing large amounts of PBSCs, which
can then be safely employed to support multiple courses of
HDDC. This study was supported by a grant from Istituto Onco-
logico Romagnolo.
Chemogene treatment consisting of recombinant replica-
tion defective adenovirus-p27, docetaxel and vinorelbine
induces apoptosis in chemoresistant aneuploid metastatic
colon carcinoma characterised by overexpression of cyclin
D1,K-Ras and HER-2/neu(c-erbB2)
J. Giannios, E. Michailakis. Department of Clinical Oncology, General State
Hospital of Athens,Greece
We obtain tumour cells from a chemoresistant patient with
metastatic colon Ca. Flow cytometry has exhibited aneuploid
DNA. The expression pattern of p27,K-Ras, HER-2/neu,cyclin
D1 and apoptotic factors (gene, mRNA transcript, protein) was
quantitatively analysed by PCR, RT-PCR, Northern-blot, IHC
and ELISA. Colon Ca cells were characterised by overexpression
of K-Ras, HER-2/neu, cyclin D1 and p27/kip1 mutations that
decrease p27/kip1 protein levels. We aim to eradicate these
tumour cells by enhancing levels of p27 with adenoviral wtp27
transfection leading to cyclin D1 downregulation which will inac-
tivate HER-2/neu – K-Ras pathway allowing induction of apopto-
sis after synergistic antimitotic treatment with docetaxel and
vinorelbine. Post-treatment,we observe replacement of wt p27
function after adenoviral transfection leading to higher levels of
p27 which downregulates cyclin D1. This caused downregulation
of HER-2/neu and K-Ras pathway. Flow cytometry exhibited
diploid DNA. Inactivation of HER-2/neu and K-Ras led to cir-
cumvention of chemoresistance allowing docetaxel and vinorel-
bine to exert their antimitotic action eradicating the colon Ca cells
via induction of apoptosis or PCD by activation of caspase-
3/CPP32 pathway. TEM exhibited morphological signs of D2
apoptotic stage forming apoptotic bodies which were phagocy-
tosed by adjacent tumour cells leading to a bystander killing
effect.MTT and BrdU analysis of treated colon Ca cells exhibited
great reduction of metabolic activity and DNA synthesis, respec-
tively, compared to untreated controls.Concluding,by establishing
wt p27 function we blocked cyclin D1 which led to inactivation of
the chemoresistant pathway of HER-2/neu and K-Ras eradicating
the colon Ca cells after synergistic antimitotic treatment with doc-
etaxel and vinorelbine.
Influence of mesna on the pharmacokinetics of cisplatin
and carboplatin in pediatric cancer patients
S.B. Kangarloo,1 J.E.A. Wolff,2 S. Glück.1 1Department of Oncology, Fac-
ulty of Medicine, University of Calgary, Tom Baker Cancer Centre, Calgary, AB,
Canada; 2Klinik St. Hedwig, Steinmetzstrasse 1-3, 93049 Regensburg, Germany
Background: Mesna, a reactive thiol, often encounters platinum
drugs (Pt-drugs) cisplatin and carboplatin in combination protocols
involving oxazaphosphorines and Pt-drugs. This co-administration
might be unfavorable based on the inactivation of Pt-drugs by
thiol groups in vitro. 
Purpose: To investigate whether mesna inﬂuences the pharma-
cokinetics of Pt-drugs when co-administered with cisplatin or car-
boplatin. 
Methods: The pharmacokinetics of Pt-drugs was investigated in
29 pediatric patients receiving either cisplatin or carboplatin in a
combination with or without mesna. Total elemental Pt (TPt) and
ultrafilterable Pt (UFPt) levels in serum were determined by
atomic absorption spectrometry. 
Results: In cisplatin patients, a decrease in the distribution
clearance of TPt was observed when mesna was co-administered
(CLd, 2.2 ± 0.1 mL/min.kg; n=3), compared to cisplatin without
mesna (CLd, 4.8±1.5 mL/min.kg; n=5), (P=0.029, t-test). This
might have been caused by an influence of mesna in slowing
down the protein binding of cisplatin since a trend (P=0.057) in
prolonged distribution half-life of TPt was also observed when
mesna was present (t1/2_, 65±21 min; n=3) compared to cisplatin
without mesna (t1/2_, 32±18 min; n=5). However, the impact of
these changes on the area under the concentration time curve
(AUC), total clearance (CLt), and volume of distribution (V) for
TPt and UFPt species was hardly noticeable. In carboplatin
patients, when mesna was co-administered: (AUC, 2.5±0.4 mg·
min/mL·400 mg/m2; n=6), (CLt, 6.8±5.1 mL/min·kg; n=6), and
(V, 0.7±0.4 L/kg; n=6) for UFPt specie was not significantly
different form when carboplatin was administered without
mesna: (AUC, 2.3±1.3 mg · min/ml · 400 mg/m2; n=5), (CLt,
5.8±4.6 mL/min·kg; n=5) and (V, 1.1±1.1 L/kg; n=5). 
Conclusion: Mesna does not inﬂuence the pharmacokinetics of
cisplatin and carboplatin in pediatric patients. Thus, it is safe to
co-administer mesna with the Pt-drugs, provided that the agents
are not mixed in solution prior to infusion into the patients.
Pharmacokinetics of once daily IV Busulfan in a myeloab-
lative/ reduced toxicity conditioning regimen for allo-
geneic transplantation in myeloid leukemia
T. Madden, M. deLima, M. Shahjahan, D.R. Couriel, B. Pierre, J.L.
Gajewski, S. Giralt, M.L. Donato, J.A. Russell, R.E. Champlin, B.S.
Andersson. University of Texas M D Anderson Cancer Center, Houston, Texas,
USA
We used a myeloablative conditioning program with Fludara-
bine (Flu) and IV Busulfan (Bu): Fludarabine, 40 mg/m2 IV daily
for 4 days, each dose followed by IV Bu, 130 mg/m2 IV over 3 hr.
After 2 rest days marrow/stem cells were given. 
Results: 23 patients were treated, 14 with active disease and 9 in
remission. Twelve were males and 11 females with a median age
of 43 years (21-57), 13 had family donors and 10 unrelated donors.
All patients engrafted (ANC 500) at a median of 13 days (10-22).
By DNA polymorphisms 17 of 19 patients were complete
chimeras at day 30, 2 were 97-98% chimeras, and in 4 the results
are pending. Once-daily IV Bu-Flu was well-tolerated, the only
toxicity was moderately severe mucositis in 11 patients, no one died
of treatment-related complications in the ﬁrst 100 days. Pharma-
cokinetic (PK) studies on days 1 and 3 (or 4) yielded the following
mean (range) parameters: T1/2_ = 3.1 hr (1.6-6.1), Bu plasma
clearance = 2.4 ml/min/kg (1.3-3.9), daily AUC = 5,516 µMol-min
(3,990-8,271). The PK parameters did not differ significantly
between days, and when compared in aggregate, they demon-
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strated linear metabolism without drug accumulation. When we
compared this with Bu PK data we previously obtained for IV Bu
at 0.8 mg/kg every 6 hr × 16 doses, the observed PK parameters
were very similar and demonstrate linear Bu pharmacokinetics.
Once-daily dosing provides consistent Bu exposure (AUC), while
avoiding the drug accumulation seen from the ﬁrst to subsequent
doses with q-6-hr dosing.
Gene expression in undifferentiated mesenchymal stem
cells from adult human bone marrow supports multipo-
tential differentiation capacity
L.P. Mueller, J. Luetzkendorf, H. Simon, A. Grothey, H.J.
Schmoll. Department of Hematology/Oncology, Martin-Luther-University of
Halle, Germany
Rationale: Hematopoietic differentiation of proliferating mes-
enchymal stem cells (MSC) may provide a source for transplantation
after myeloablative therapy. An analysis of gene expression in MSC,
which could help to evaluate their therapeutic potential is missing.
Methods: Adherent cells were isolated from bone marrow of
3 (I-III) voluntary adult human donors. Proliferating cells were
characterized as MSC (CD34–/CD14–/CD45–CD29+/CD105+/
CD166+) by ﬂow-cytometry. RT-PCR was performed for collagen
II, TGFβ receptor II (TGFβ R-II), FGF-receptor I (FGFR-I),
Activin-receptorIIB (ACTR-IIB), retinoic acid receptor-α (RAR-α),
BMP receptor II (BMPR-II) and Oct4. Analysis for expression of
selected proteins was performed by Western-blotting. 
Results: In all donors a homogenous MSC population could be
isolated. RT-PCR revealed expression of TGFβ R-II, FGFR-I,
ACTR-IIB and RAR-α in all donors. BMPR-II was only detected
in donor III at passage 2-5 but not in donor I and II at passage 3.
Interestingly, Oct4 expression was seen in all donors except at pas-
sage 4 and 5 in donor III. No expression of collagen II, i.e. no
osteogenic differentiation was observed. Although expression of
Oct4 is characteristic for embryonic stem cells, western-blotting
with anti-Oct4 showed the 45kDa protein in MSC of all donors at
passage 2-4. 
Conclusions: Plastic-adherent cells from adult human bone
marrow with stem cell characteristics express multiple differentia-
tion markers. The data regarding Oct4 need further conﬁrmation
but suggest an immature nature of MSC. The expression of
BMPR-II was variable and requires further investigation. In con-
clusion, the expression pattern of these markers in MSC correlates
with a multipotential differentiation capacity.
Transplantation of ex vivo expanded mobilised blood
CD34+ cells enhances both neutrophil and platelet recov-
ery following high dose chemotherapy (HDT)
H.M. Prince,1 D.N. Haylock,1 D. Wall,1 L. Barber,1 L. Mints-
Kotowska,1 L. Teoh,1 R. Mrongovius,2 P.J. Simmons.1 1Centre for Blood
Cell Therapies, Division of Haematology and Medical Oncology, Peter MacCallum
Cancer Institute (PMCI1, and 2Amgen Australia, Melbourne, VIC
Background: One possible means of abrogating cytopenias fol-
lowing HDT is by infusion of ex vivo generated neutrophil and
megakaryocytic precursor cells either alone or with unmanipu-
lated (unM) mobilised blood progenitor cells. 
Methods: Patients (pts) with refractory locally advanced or
metastatic breast cancer were entered into this clinical trial of repet-
itive cycles (c) of HDT with cyclophosphamide, thiotepa and pacli-
taxel. The protocol design involves 3 cohorts of 3 pts; each cohort
receiving unM cells +/- Isolex 300i selected-CD34+ ex vivo
expanded (XV) cells at different intervals. Ex vivo expansion of
CD34+ cells was performed by culture in X-VIVO-10 media sup-
plemented with 0.5% HSA (Buminate, Baxter Hyland) and G-CSF
(filgrastim), SCF (stemgen), and PEG-rHuMGDF (provided by
Amgen. 
Note: PEG-rHuMGDF is not in commercial development).
Cultures were initiated in 3L Stericell culture ﬂasks (1L/ﬂask) and
incubated for 12d under GMP conditions, and subsequently gently
washed (Haemonetics Haemolite-2) and concentrated to 300ml
prior to infusion (d0). All patients received daily filgrastim
(5mcg/kg) from d1. 
Results: 5/9 planned pts have been enrolled. Results from
Cohort 1 (n=3) (unM cells infused after c1 of HDT, and both unM
and XV cells infused after c2 and c3): There was a mean 43-fold
(range: 30-67) expansion of total cell numbers and development of
both neutrophil and platelet precursor cells, as deﬁned by multipa-
rameter immunophenotyping. Pts received a mean of 8.0 × 109
(range: 5.2-10.3) XV cells with each XV-supported cycle. To eval-
uate the impact on hemopoietic recovery of XV cells, the XV-sup-
ported cycles were compared to a historical group receiving unM
cells (n=124 cycles) and each pt also acted as an ‘internal control’ as
c1 of HDT was supported by unM cells alone. XV-supported
cycles consistently resulted in a higher ANC nadir (>0.2 v <0.01 ×
109/L) with faster recovery to ≥0.5 × 109/L (7d vs 10d) and ≥1.0
(7d vs 11d). Plt recovery was faster following XV-supported cycles:
≥20 × 109/L (8d v 14d), ≥50 × 109/L (12d v 19d). Furthermore
there was a faster time to platelet independence (10d vs 14d) with
2 of 3 pts not requiring plt transfusion (cf. all pts in historical group). 
Conclusion: This data demonstrates for the ﬁrst time that ex vivo
generated haemopoietic cells can enhance platelet recovery fol-
lowing HDT. The trial continues to accrue with plans to apply
this strategy to other malignancies requiring HDT.
Audit of outcomes of breast cancer patients undergoing
high hose chemotherapy and hematopoietic stem cell
transplantation
A. Raptis, O. Ballester, J. Grutsch, S. Williams, B. Tan, P. Wilcox, M.
Payne, B. Braun. Midwestern Regional Medical Center Cancer, Cancer treat-
ment Centers of America, Zion, Illinois, USA
We audited the survival outcomes of breast cancer patients
undergoing autologous stem cell transplant (ASCT) in a case
series from Midwestern Regional Medical Center at Zion Ill. We
retrospectively reviewed the medical charts of patients undergoing
ASCT between September 1994 and September 2001. We meas-
ured the survival of seventy-eight consecutively treated patients
using univariate survival statistics. We report on the survival of
these patients after stratifying for the known prognostic variables.
Currently, forty-ﬁve of the patients have died. Demographically,
the patients’ ages ranged from 29 to 69 years (median 49.5 yrs). At
the time of transplant 52 patients had metastatic disease, while the
others were stage II/III breast cancer. The median hospital stay
was 26 days (range 10 to 74). The median time to engraphment
was 11 days (range 5 to 16 days). Twelve patients died within 100
days of transplant. The median, 2 and 5-year survival was 110
weeks, 54% and 27% respectively for all patients. Patients
younger than 45 years had a median survival of 179 weeks, while
older patients’ median survival was 73 weeks (two tailed Wilcoxon
p = 0.0076). The median survival of patients with metastatic dis-
ease was 73 weeks, but the ﬁve-year cumulative survival was 12%.
On the other hand, the ﬁve-year cumulative survival of patients
with stage II/III was 58%. The interesting finding was that the
five-year cumulative survival of patients with metastatic breast
cancer was over 10%. This result has been infrequently reported
by other centers. 
The acute toxicities associated with the use of donor lym-
phocyte infusions in patients undergoing autologous bone
marrow transplantation
A. Raptis, O. Ballester, J. Grutsch, S. Williams, B. Tan, P. Wilcox, M.
Payne, B. Braun. Midwestern Regional Medical Center Cancer, Cancer treat-
ment Centers of America, Zion, Illinois, USA
There are indications that the use of donor lymphocytes infu-
sions (DLI) promises to improve the outcomes of patients using
autologous BMT. This study investigates the incidence of treat-
ment related mortality and morbidity associated with the use of
this therapy in a consecutively treated series of eighteen patients
treated at Midwestern Regional Medical Center, Zion Illinois
between January 1999 and July 2001. The diagnostic distribution
was breast cancer (6), chronic lymphocytic leukemia (1), multiple
myeloma (MM) (7), non-Hodgkins lymphoma (3), and ovarian
cancer (1). The median age of the patients was 48 years (range 31
to 62). Fifteen of the lymphocyte donors were siblings and the rest
were children. All donors had at least three of six HLA matches.
Eight patients developed graft vs. host disease (GVHD) following
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infusion, and all had self-limiting GVHD. The median time to
neutrophil engraphment was 13 days (range 11 to 16). All patients
had antibiotic therapy (6 neutropenic fevers without positive cul-
tures, 3 gram negative, nine gram positive cultures). Four patients
died during transplant (cerebral brain hemorrhage, pulmonary
hemorrhage, progression of disease, aspergillus fumigatus pneu-
monia) and another patient died within 100 days (progression of
disease). Eight patients have died and the median survival is
91 weeks with a 40% two-year survival. We found that MM
patients had a statistically signiﬁcant better survival than the other
patients, with an 87% and 17%, two year cumulative survival,
respectively (Log Rank = 0.0387).
Adjuvant and neoadjuvant use of high dose mitoxantrone,
vinblastine, cyclophosphamide (MVC) and autologous
stem cell transplantation (ASCT) for patients with poor
prognosis stage II/III breast cancer (BrCa)
D.A. Stewart, J.M. Nabholtz, P. Greggie, J.D. Ruether, A. Chaudhry,
J. Russell, P. Craighead, A.H.G. Paterson, M. Smylie, J. Mackey, S.
Glück. Foothills Hospital and Tom Baker Cancer Centre in Calgary, and Cross
Cancer Institute in Edmonton, Alberta, Canada
This phase II study evaluated a novel high dose regimen that
incorporated active BrCa agents with differing mechanisms of
action. Eligiblity included: stage II BrCa with ≥7+ axillary nodes
(AxLN), stage III BrCa with ≥4+ AxLN, or locally advanced BrCa
(LABC). Pts had no deﬁnite metastases by CXR, bone scan and
liver ultrasound. By Northern Alberta Breast Registry data, all
such pts had expected 1, 2, and 5 year distant disease-free survival
(DDFS) rates no better than 70%, 55%, and 40%, respectively.
Pts received FAC × 4, then M-63mg/m2 V-12.5mg/m2 and
C-6g/m2 with ASCT. From 04/95 to 12/98, 92 pts (Calgary=52,
Edmonton=40) aged 21-65 yrs (median 45) were enrolled. 25 pts
(aged 21-51yr) were treated pre-operatively for LABC (T4N1-
2=17, T3N1-2=8) of whom 12 achieved a near pCR (pT0 or
T1aN0M0) and 15 had negative AxLN at mastectomy. The other
67 pts were treated post-op for T1-2 (41) or T3-4 (26) disease and
a median of 10+ AxLN (7-29+ AxLN). The MVC regimen
resulted in no early transplant-related mortality. One late death
occurred from 20 AML. The median left ventricular ejection frac-
tion was maintained from 63% (50-81%, n=92) at baseline to 58%
(38-80%, n=77) 3 months, and 59% (40-70%, n=33) 2yrs post-
MVC. With a median follow-up of approximately 4 yrs post-
mastectomy the DDFS and overall survival rates are 67% and
68%, respectively with no signiﬁcant difference between the pre-
and post-operative groups. In conclusion, MVC/ASCT is feasible,
reasonably safe, and gives encouraging early DDFS rates for poor
prognosis BrCa pts.
Micro-metastasis in apheresis products predict shorter
progression free survival and overall survival in patients
with breast cancer undergoing high dose chemotherapy
(HDCT) and autologous blood stem cell transplantation
(ABSCT)
R. Syme, M. Kelly, M. Rodriguez-Galvez, J. Luider, Y. Auer, J.
Klassen, D. Morris, C. Brown, J. Russel, D. Stewart and S. Glück.
University of Calgary and Tom Baker Cancer Centre, Calgary, Alberta, Canada
The presence of cancer cells in autografts of patients with
breast cancer has been described to be of either prognostic
value or directly leading to relapse. Previously, we demon-
strated that apheresis products (AP) collected after second or
third cycle of induction chemotherapy (ICT) carry significantly
lower likelihood of tumour cell contamination. In this study,
we examined the prognostic potential of micro-metastasis in
the autografts. Data from 74 patients with advanced breast can-
cer who were treated with HDCT and ABSCT were analysed.
All patients who responded to ICT were treated with one addi-
tional cycle of CT plus G-CSF until apheresis was completed.
The target to collect was at least 5 × 106 CD34+ cells/kg body
weight for each patient. We used pan-cyotkeratin-FITC conju-
gated antibodies with appropriated controls upon flow-
cytometry to detect contaminating breast cancer cells in the
apheresis products. Of the 74 patients in our study, 15 had
more than 3 breast cancer cells detectable in their AP and 59
patients were shown to have less than 3 cells detectable in their
AP. When patients with more than 3 contaminating cancer
cells were compared to patients with 0-3 cells identified in
their AP, we found statistically significant differences in pro-
gression free survival and overall survival (p=0.01 and 0.01
respectively, log rank test). We conclude that patients with
more than 3 contaminating cells in their AP detected by our
method represent a poor prognosis group.
Cultured dendritic cells can prime potent CTL in lymphoma
R. Syme, M. Kelly, D. Stewart, S. Glück. University of Calgary and Tom
Baker Cancer Centre, Calgary, Alberta, Canada
In a significant number of intermediate and high grade non-
Hodgkin’s lymphoma the prognosis is uniformly poor, and dis-
ease recurrence is still great. Interest therefore has developed
in using dendritic cells to enhance immune responses. Previ-
ously, we have shown that we can culture functional monocyte-
derived dendritic cells (DC) from a variety of lymphoma
patients. We undertook the following study to determine if we
could induce CTL responses against lymphoma cells. DC were
generated from PBMC by culturing adherent cells in the pres-
ence of IL-4 and GM-CSF and then pulsing them with tumor
cell lysate from a lymphoma cell line. PBMC were stimulated
in the presence of these DC and then used in an LDH based
cytotoxicity assay. We could generate cytotoxicity (16-27%) at
a 5:1 effector to target cell ratio. By utilizing either whole pro-
tein or RNA from the tumor cell line as an antigen source we
were able to improve cytotoxicity (34-100%) at the same E:T
ratios. To further enhance cytotoxicity the immunostimulatory
ability of DC was increased by maturing the cells. After antigen
pulsing the cells they were then matured overnight in the pres-
ence of monocyte conditioned media, or TNF-α. At a 2:1 E:T
ratio we were able to increase cytotoxicity levels 3 to 4 fold.
Together this data suggests that we can generate potent cyto-
toxic responses towards lymphoma cells, and that by manipu-
lating the antigen or DC we can induce responses at desired
low E:T ratios. Our next step is to assess these parameters in a
clinical trial.
Biological purging of breast, lymphoma and myeloma cells
using reovirus in human hematopoetic stem cell trans-
plantation
C. Thirukkumaran, J. Luider, M. Nodwell, T. Alain, S. Lupichuk, T.
Cheng, D. Stewart, P. Lee, D. Morris. Tom Baker Cancer Centre, Calgary,
Alberta, Canada
Introduction: Stem cell rescue after high-dose ablative therapy
in autologous transplantation is extensively used for treatment of
many solid and hematopoetic cancers. Gene marking studies sug-
gest, occult clonogenic tumor cells within the autograft may con-
tribute to relapse. We have demonstrated the selective oncolytic
property of reovirus in vitro, in vivo and ex vivo. In the present
study we tested the hypothesis that reovirus could successfully
purge cancer cells in autografts. 
Methods/results: Human breast cancer, lymphoma and
myeloma cell lines were infected with reovirus (serotype3). Cells (+/-
virus) were harvested at hours 0, 24, 48,72, 96 and 168 and ana-
lyzed for cytopathic effect (CPE), viable cell number and apop-
totic indices. Cell viability decreased signiﬁcantly with virus treat-
ment corresponding with an increase in apoptotic markers. 35S
methionine labeling of virus proteins indicated reovirus incorpo-
ration and disruption of host cell protein synthesis as early as
24hr. No oncolytic properties of reovirus could be demonstrated
for CD 34+ stem cells even after 72hrs of exposure (35S methion-
ine labeling +/- GCSF, colony forming assays). Admixtures of
apheresis product with cancer cells treated with reovirus showed
complete purging of breast and myeloma cells at 1% contamina-
tion as detected by PCR or ﬂowcytometry. Signiﬁcant purging of
lymphoma cells was observed at 1% contamination and at 0.01%
complete purging was attained. 
Conclusions: Our results indicate the ex vivo use of an
oncolytic virus is an attractive purging strategy for autologous
stem cell transplants.
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Characterization of dendritic cells from peripheral blood
mononuclear cells of Taiwanese melanoma patients for
DC-based immunotherapy
C. Wang,1 J. Chang,1 J. Hsieh, Y. Shen, C. Chuang,2 C. Liu, S. Liao.
1Division of Hematology-Oncology, Department of Internal Medicine; 2Division of
Urology, Department of Surgery, Chang Gung Memorial Hospital; and Graduate
Institute of Clinical Medicine, Chang Gung University, Taoyuan 333, Taiwan
Dendritic cells (DCs) in Caucasian melanoma patients could
present antigens and induced speciﬁc T cell response (Anticancer
Research, 1999; 2000). Six × 107 peripheral blood mononuclear
cells (PBMCs) from 6 Taiwanese melanoma patients were incu-
bated in similar approach. The adherent cells were cultured in
GM-CSF and IL-4 for 7 days. Different monoclonal antibodies
were utilized for phenotype analysis (see Table).
Markers HLA-DR CD1a CD40 CD80 CD83 CD86
Control DCs(%) 97±0.5 38±13 48±32 87±6 5±3 90±5
TNF-α DCs(%) 98±1 53±17 77±18 91±9 39±14 94±6
One × 105 allogeneic responder T cells were cocultured with
variable amount of irradiated DCs in standard mixed lymphocyte
reaction (MLR) in 4 cases. All revealed a proliferative response.
Autologous short-term tumor cells were obtained in 4 cases, and
apoptosis were induced when treated with actinomycin D in
3 cases. A two-fold increase of Annexin V-positive (12.9%±0.54%)
population was seen. Autologous T cells were treated with antigen
loaded DCs in 4 cases. Th1 response was seen in case 2 (IFN-γ
level 878.27±71.76 pg/ml and IL-10 level 9.01±3.23 pg/ml).
Mixed Th1 and Th2 responses were seen in case 1 and 3. In
case 2, stimulated by apoptotic body-pulsed DCs, T-cells showed
an increased (2-fold) cytolytic activity on autologous melanoma
cells (Fig.). In conclusion, DCs generated from PBMC of Tai-
wanese melanoma patients could stimulate autologous T cells thus
induced a cytolytic activity on melanoma cells.
TNF-α transgene-expressing dendritic cells undergo aug-
mented cellular maturation, and induce more robust T
cell activation and antitumor immunity than dendritic
cells generated in recombinant TNF-α
J. Xiang. Research Unit, Saskatchewan Cancer Agency, Department of Oncology,
University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Tumor antigen presentation by dendritic cells (DCs) to T cells
in lymphoid organs is crucial for induction of anti-tumor
immune responses. It has been previously reported that tumor
necrosis factor-alpha (TNF-α) is required for DC activation and
subsequent induction of optimal immune responses, and thus
DCs for antitumor vaccination are often generated by culture in
exogenous TNF-α. In the present study, we investigated the
effect on antitumor immunity of vaccination with Mut1 tumor
peptide-pulsed DCs engineered to express a TNF-α transgene.
Our data shows that transfection of DCs with recombinant aden-
ovirus AdV-TNF-α resulted in greater maturation of the DCs
than occurred with control DCs cultured in exogenous TNF-α,
as determined by up-regulated expression of proinflammatory
cytokines (e.g., IL-1β and IL-18), chemokines (e.g., IP-10 and
MIP-1β), the CC chemokine receptor CCR7, and immunologi-
cally important cell surface molecules (CD40, CD86 and ICAM-1).
These transgenic DCs (i) stimulated stronger allogeneic T cell
responses in vitro and T cell activation in vivo, (ii) displayed
2.4-fold enhanced chemotactic responses to the MIP-3β in vitro
(p<0.05) and, (iii) perhaps most importantly, trafficked into the
draining lymph nodes dramatically (7 fold, p<0.01) more effi-
ciently than the control DCs. Our data also demonstrates that
vaccination of mice with Mut1 peptide-pulsed, AdV-TNF-α-
transfected DCs stimulated more efficient in vitro Mut1-specific
CD8+ cytotoxic T cell responses and solid tumor immunity in
vivo, when compared to the in vitro TNF-α-cultivated DCs.
Thus, DCs engineered to secrete TNF-α may offer a new strat-
egy in DC cancer vaccines.
